Make better-informed clinical decisions
suPARnostic® eliminates doubt and supports your clinical decisions to discharge or admit patients based on prognostic evidence.
Discharge more patients
suPAR is a prognostic biomarker that reflects the extent of activation of the immune system non-specific to any individual disease.
Implementing suPARnostic® in acute clinical care allows you to identify 34%1 more patients who can be discharged. This reduces crowding and leads to lower healthcare costs.
A low suPAR level (under 4 ng/ml) indicates a good prognosis and supports the decision to discharge the patient.
A high suPAR level (over 6 ng/ml) indicates the presence, progression, and severity of disease, organ damage, mortality risk and supports further clinical attention.
* Ref. 2016 EMJ Rasmussen et al.
How to interpret suPAR results
suPAR level < 4 ng/mL
Supports patient discharge
suPAR level > 6 ng/mL
Supports patient hospitalisation
Improve patient outcomes and lower healthcare costs
Prognostic, data-based risk stratification increases the efficiency of the emergency department and improves patient outcomes3,4.
Implementing suPARnostic® shortens the average patient length-of-stay by 6%* per patient and reduces crowding and hospital costs.2
“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”
– MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen
NEW STUDY:
Early anakinra treatment of COVID-19 patients guided by suPAR saves lives
Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.
2. Schultz et al. Disease Markers, 2019, 10;1-8
3. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Kyriazopoulou et al. Nat Med 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z.
4. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Rasmussen et al. Emerg Med J 2016;33:769–775. doi:10.1136/emermed-2015-205444
